[Form 4] KEWAUNEE SCIENTIFIC CORP /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Donald T. Gardner III, Chief Financial Officer and director, reported a sale of 3,000 shares of Kewaunee Scientific Corp (KEQU) on 10/09/2025 at a weighted average price of $42.76 per share. After the transactions, he beneficially owned 11,564 shares. The filing states the sale occurred in multiple trades priced between $42.68 and $43.57, and the reporting person offered to provide a breakdown of shares sold at each price upon request. The Form 4 is signed and dated 10/10/2025, indicating timely disclosure of the insider transaction.

Positive

• Timely disclosure of the insider sale via a signed Form 4 dated 10/10/2025
• Transparency about trade price range ($42.68–$43.57) and offer to provide per-trade details
• Significant retained stake of 11,564 shares after the sale

Negative

• Reduction in insider holdings by 3,000 shares on 10/09/2025
• No statement in the filing that the sale was made under a 10b5-1 plan (no such box checked)

Insights

Corporate Governance Analyst

Insider disclosed a modest share sale and retains a meaningful position.

The CFO sold 3,000 shares at a weighted average price of $42.76, reducing his stake to 11,564 shares. This is a clear, documented change in beneficial ownership reported on a Form 4 and the filing offers further granularity on execution prices between $42.68 and $43.57.

The primary dependency is whether the sale was routine (e.g., diversification or liquidity) or part of a plan; the filing does not state a 10b5-1 plan. Investors may observe insider activity near 10/09/2025 as a near-term signal of personal trading but should not infer motive from the filing alone.

Market Compliance Specialist

Filing shows compliance with Section 16 reporting requirements.

The Form 4 includes the required transaction date, quantities, weighted average price, and a signer’s certification dated 10/10/2025. The disclosure that sales occurred across prices and the offer to provide per-trade detail supports transparency in reporting execution details.

Key items to monitor are any further Form 4 filings from the same reporting person and whether future filings indicate a pattern of disposals or purchases over the following weeks to months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gardner Donald T. III

(Last) (First) (Middle)

2700 WEST FRONT STREET

(Street)

STATESVILLE NC 28677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S		3,000	D	$42.76(1)	11,564	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.68 to $43.57 inclusive. The reporting person undertakes to provide Kewaunee Scientific Corporation ("Kewaunee"), any security holder of Kewaunee, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Donald T. Gardner III	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KEQU CFO Donald T. Gardner III report on Form 4?

He reported a sale of 3,000 shares on 10/09/2025 at a weighted average price of $42.76, leaving him with 11,564 shares.

At what prices were the KEQU shares sold on 10/09/2025?

The filing states the shares were sold in multiple transactions at prices ranging from $42.68 to $43.57, with a reported weighted average of $42.76.

Does the Form 4 indicate the sale was under a 10b5-1 trading plan?

No. The filing does not indicate that the transaction was made pursuant to a 10b5-1 plan and the 10b5-1 box is not checked.

When was the Form 4 signed and filed?

The filing is signed by Donald T. Gardner III and dated 10/10/2025.

How many shares does the CFO hold after the sale?

He beneficially owns 11,564 shares following the reported transactions.